Chemed Corp. Stock
Chemed Corp. Stock
Heavy losses for Chemed Corp. today as the stock fell by -€35.000 (-6.190%).
Currently there is a rather positive sentiment for Chemed Corp. with 4 Buy predictions and 0 Sell predictions.
With a target price of 588 € there is a slightly positive potential of 10.94% for Chemed Corp. compared to the current price of 530.0 €.
So far the community has only identified positive things for Chemed Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Chemed Corp. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Chemed Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Chemed Corp. | -6.190% | -4.505% | -10.169% | 9.053% | 1.923% | 41.711% | 81.445% |
| Amn Healthcare Svs | 0.960% | 0.000% | -7.895% | -32.258% | -21.642% | -18.605% | 17.872% |
| Ensign Group Inc. | -1.800% | -1.786% | -2.655% | - | 6.796% | - | - |
| Select Medical Holdings | - | 3.226% | -7.246% | -5.185% | 18.519% | -17.419% | 103.207% |
Comments
Chemed Co. (NYSE: CHE) had its price target raised by analysts at Royal Bank of Canada from $604.00 to $712.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CHE provided by MarketBeat
Chemed Co. (NYSE: CHE) had its price target raised by analysts at Oppenheimer Holdings Inc. from $625.00 to $650.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CHE provided by MarketBeat
Chemed Co. (NYSE: CHE) had its price target raised by analysts at Oppenheimer Holdings Inc. from $590.00 to $625.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CHE provided by MarketBeat
News
Chemed Reports First-Quarter 2024 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
VITAS Completes the Previously Announced Purchase of Assets of Covenant in Florida and Alabama
VITAS Healthcare Corporation, a wholly-owned subsidiary of Chemed Corporation (“Chemed”) (NYSE: CHE) announced the completion of the previously announced purchase of all hospice operations and an
Chemed To Report First-Quarter 2024 Earnings April 24, Related Conference Call To Be Held On April 25
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2024, on Wednesday, April 24, 2024, following the close of trading on the